Abstract:Free Fatty Acid Receptor 4 (FFAR4), a G-protein-coupled receptor, is responsible for triggering intracellular signaling pathways that regulate various physiological processes. FFAR4 agonists are associated with enhancing insulin release and mitigating the atherogenic, obesogenic, pro-carcinogenic, and pro-diabetogenic effects, normally associated with the free fatty acids bound to FFAR4. In this research, molecular structure-based machine-learning techniques were employed to evaluate compounds as potential agonists for FFAR4. Molecular structures were encoded into bit arrays, serving as molecular fingerprints, which were subsequently analyzed using the Bayesian network algorithm to identify patterns for screening the data. The shortlisted hits obtained via machine learning protocols were further validated by Molecular Docking and via ADME and Toxicity predictions. The shortlisted compounds were then subjected to MD Simulations of the membrane-bound FFAR4-ligand complexes for 100 ns each. Molecular analyses, encompassing binding interactions, RMSD, RMSF, RoG, PCA, and FEL, were conducted to scrutinize the protein–ligand complexes at the inter-atomic level. The analyses revealed significant interactions of the shortlisted compounds with the crucial residues of FFAR4 previously documented. FFAR4 as part of the complexes demonstrated consistent RMSDs, ranging from 3.57 to 3.64, with minimal residue fluctuations 5.27 to 6.03 nm, suggesting stable complexes. The gyration values fluctuated between 22.8 to 23.5 nm, indicating structural compactness and orderliness across the studied systems. Additionally, distinct conformational motions were observed in each complex, with energy contours shifting to broader energy basins throughout the simulation, suggesting thermodynamically stable protein–ligand complexes. The two compounds CHEMBL2012662 and CHEMBL64616 are presented as potential FFAR4 agonists, based on these insights and in-depth analyses. Collectively, these findings advance our comprehension of FFAR4's functions and mechanisms, highlighting these compounds as potential FFAR4 agonists worthy of further exploration as innovative treatments for metabolic and immune-related conditions.

A Selectivity Study of FFAR4/FFAR1 Agonists by Molecular Modeling

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Mechanistic Studies on the Stereoselectivity of FFAR1 Modulators.

Computational Insights into Molecular Activation and Positive Cooperative Mechanisms of FFAR1 Modulators.

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Predicting FFAR4 agonists using structure-based machine learning approach based on molecular fingerprints

Structural insights into endogenous ligand selectivity and activation mechanisms of FFAR1 and FFAR2

Synthesis and evaluation of 3-(4-(phenoxymethyl)phenyl)propanoic acid and N-phenylbenzenesulfonamide derivatives as FFA4 agonists.

A high-throughput structural dynamics approach for identification of potential agonists of FFAR4 for type 2 diabetes mellitus therapy

Label-free Cell Phenotypic Study of FFA4 and FFA1 and Discovery of Novel Agonists of FFA4 from Natural Products.

3D-QSAR and Molecular Dynamics Study of Isoxazole Derivatives to Identify the Structural Requirements for Farnesoid X Receptor (FXR) Agonists

Discovery of novel FFA4 (GPR120) receptor agonists with β-arrestin2-biased characteristics

Distinct binding hotspots for natural and synthetic agonists of FFA4 from in silico approaches

Identification and target-pathway deconvolution of FFA4 agonists with anti-diabetic activity from Arnebia euchroma (Royle) Johnst

Addressing free fatty acid receptor 1 (FFAR1) activation using supervised molecular dynamics

Molecular Dynamics Exploration of Selectivity of Dual Inhibitors 5M7, 65X, and 65Z Toward Fatty Acid Binding Proteins 4 and 5.

Elucidating the Binding Mechanism of LPA Species and Analogs in an LPA4 Receptor Homology Model

Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold

Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation

Design, Synthesis and Structure-Activity Relationship Studies of Novel Phenoxyacetamide-Based Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes

Exploration of N-Arylsulfonyl-indole-2-carboxamide Derivatives as Novel Fructose-1,6-bisphosphatase Inhibitors by Molecular Simulation